Clinical Trial Update: Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing MEK162 (binimetinib) to dacarbazine in NRAS-mutant unresectable or metastatic melanoma has completed; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• MEK162 (binimetinib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic or Unresectable Cutaneous Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2021-03-22